Compare Amphastar Pharmaceuticals Inc (AMPH) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Levi Strauss & Co. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.36 (market cap $863.95M), while Levi Strauss & Co. trades at $22.84 (market cap $9.09B). The key difference: Levi Strauss & Co. is far larger — about 10.5× Amphastar Pharmaceuticals Inc's market cap, and Levi Strauss & Co. pays a 2.71% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LEVI | |
|---|---|---|
Market Cap | $863.95M | $9.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $25.53 |
52-Week Low | $16.87 | $17.92 |
Enterprise Value | $1.26B | $10.40B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Levi Strauss (LEVI) trades at $24.4, up 0.39% on the day, with a bullish fundamental backdrop including strong earnings beats and a 77.78% analyst buy rating. The stock shows a bearish technical signal overall, with neutral RSI readings and key resistance at $25. Recent news highlights a cybersecurity breach disclosed on August 7, 2026, but the company's direct-to-consumer digital strategy continues to drive growth.
Outlook remains positive with a consensus price target of $27.88, implying 14.3% upside, supported by robust profitability and raised 2026 guidance. Risks include recent cybersecurity issues, tariff pressures, and execution challenges in a competitive apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
